Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium–glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents

Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium–glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents

We investigated whether structurally different sodium–glucose cotransporter (SGLT) 2 inhibitors, when co-administered with dipeptidyl peptidase-4 (DPP4) inhibitors, could enhance glucagon-like peptide-1 (GLP-1) secretion during oral glucose tolerance tests (OGTTs) in rodents. Three different SGLT in...

Full description

Bibliographic Details
Main Authors: Takahiro Oguma, Chiaki Kuriyama, Keiko Nakayama, Yasuaki Matsushita, Kumiko Hikida, Minoru Tsuda-Tsukimoto, Akira Saito, Kenji Arakawa, Kiichiro Ueta, Masabumi Minami, Masaharu Shiotani
Format: Article
Language:English
Published: Elsevier 2016-12-01
Series:Journal of Pharmacological Sciences
Subjects:
SGLT2 inhibitor
DPP4 inhibitor
Canagliflozin
Combination treatment
Glucagon-like peptide-1
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861316301372

Internet

http://www.sciencedirect.com/science/article/pii/S1347861316301372

Similar Items